Myoderm plans global expansion into European pharma market

15 March 2011

Myoderm, a US supplier of commercial drugs for clinical research and clinical trials, says it has been granted a Wholesale Dealer License from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In addition, Myoderm has established a new partnership with a leading European pharmaceutical logistics provider.

The license agreement granted by the MHRA enables Myoderm to buy, sell and distribute pharmaceuticals within the UK. Providing more direct access to drug manufacturers across Europe, the license will facilitate Myoderm's current supply capabilities and business objectives of commercial expansion and strategic positioning within the European Pharmaceutical Market.

"Acquiring our Wholesale Dealer License and partnering with a leading European, Pharmaceutical logistics provider is critical to our continued effort to enhance our worldwide supply capabilities," says Mike Cohen, Myoderm's managing director.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK